Neumora Therapeutics (NMRA) Total Liabilities (2022 - 2026)

Neumora Therapeutics' Total Liabilities history runs 5 years deep, the most recent figure standing at $83.2 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 193.11% year-over-year to $83.2 million in Q1 2026; TTM through Mar 2026 was $83.2 million, a 193.11% increase from a year earlier, with the FY2025 full-year figure at $87.2 million, up 191.48% from the prior year.
• Total Liabilities slipped to $83.2 million in Q1 2026 per NMRA's latest filing, from $87.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $87.2 million in Q4 2025 and bottomed at $23.2 million in Q2 2024.
• The 5-year median for Total Liabilities is $30.9 million (2024), against an average of $40.4 million.
• Across the five-year window, Total Liabilities declined 7.75% in 2023 and soared 193.11% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $29.4 million in 2022, then slipped by 7.75% to $27.1 million in 2023, then climbed by 10.28% to $29.9 million in 2024, then jumped by 191.48% to $87.2 million in 2025, then decreased by 4.56% to $83.2 million in 2026.
• Per Business Quant, the three latest NMRA Total Liabilities figures stand at $83.2 million (Q1 2026), $87.2 million (Q4 2025), and $45.7 million (Q3 2025).